Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2013
11/14/2013WO2013169793A2 Methods and compositions for tdp-43 proteinopathies
11/14/2013WO2013169768A1 Multi-stage process for production of immune modulator
11/14/2013WO2013169746A2 N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl) amino)-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide
11/14/2013WO2013169741A1 Agents and devices for affecting nerve function
11/14/2013WO2013169740A2 Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression
11/14/2013WO2013169727A1 Polymorphic salt of the oxalate salt of 6 - o - ( 4 - dimethylaminoethoxy) cinnarnoyl fumagillol and methods of making and using same
11/14/2013WO2013169724A1 Implantable medical devices comprising a water - insoluble therapeutic agent and xylitol, iodine or edta
11/14/2013WO2013169704A2 TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
11/14/2013WO2013169648A1 Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
11/14/2013WO2013169646A1 Methods of maintaining, treating or improving cognitive function
11/14/2013WO2013169631A2 Wnt protein signalling inhibitors
11/14/2013WO2013169616A1 Pharmacokinetic modulation with alisporivir
11/14/2013WO2013169588A1 BICYCLIC SULFONE COMPOUNDS FOR INHIBITION OF RORy ACTIVITY AND THE TREATMENT OF DISEASE
11/14/2013WO2013169578A1 C-17 bicyclic amines of triterpenoids with hiv maturation inhibitory activity
11/14/2013WO2013169577A1 Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
11/14/2013WO2013169574A2 Aliphatic spirolactam cgrp receptor antagonists
11/14/2013WO2013169567A1 Spirolactam cgrp receptor antagonists
11/14/2013WO2013169565A1 Heterocyclic cgrp receptor antagonists
11/14/2013WO2013169563A1 Pyridine cgrp receptor antagonists
11/14/2013WO2013169546A1 Pyrazole compounds as sglt1 inhibitors
11/14/2013WO2013169538A1 Nanoparticle delivery vehicle for s-nitroso-n-acetyl cysteine and uses thereof
11/14/2013WO2013169520A1 Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
11/14/2013WO2013169479A1 Compositions and methods of treatment of drug resistant cancers
11/14/2013WO2013169458A1 Pharmaceutical compositions and methods for treating, controlling, ameliorating, or reversing conditions of dry eye
11/14/2013WO2013169399A1 Oxysterol analogue oxy133 induces osteogenesis and hedgehog signaling and inhibits adipogenesis
11/14/2013WO2013169397A1 Novel oxysterol analogue, oxy149, induces osteogenesis and hedgehog signaling and inhibits adipogenesis
11/14/2013WO2013169390A1 Zeaxanthin for tumor treatment
11/14/2013WO2013169355A1 Treatment of myelosuppression
11/14/2013WO2013169348A1 Process for making cgrp receptor antagonists
11/14/2013WO2013169337A1 Polymer conjugates with a linker
11/14/2013WO2013169315A1 Method for treating macular degeneration
11/14/2013WO2013169291A2 Method for inducing udp-glucuronosyltransferase activity using pterostilbene
11/14/2013WO2013169218A1 Pharmaceutical compositions of s-etodolac
11/14/2013WO2013169194A1 Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent
11/14/2013WO2013169146A1 Method for regenerating bone tissue under experimental conditions
11/14/2013WO2013169082A1 Bosentan controlled release oral preparation
11/14/2013WO2013169007A1 Sustained-release complex preparations for treating diabetes with improved drug compliance and method for preparing same
11/14/2013WO2013168826A1 Method for screening for prophylactic or therapeutic agent for diseases or disorders associated with inflammation-related feedback loop
11/14/2013WO2013168807A1 Additive for graft cell suspension, and therapeutic composition
11/14/2013WO2013168803A1 Skin-improving agent
11/14/2013WO2013168760A1 Aromatic ring compound
11/14/2013WO2013168759A1 Aromatic ring compound
11/14/2013WO2013168694A1 Non-sugar energy-production-enhancing agent
11/14/2013WO2013168693A1 Method for producing sepiapterin and tetrahydrolactoylpterin
11/14/2013WO2013168671A1 Pyrazole derivative and use thereof for medical purposes
11/14/2013WO2013168627A1 CRYSTALS OF 5'-O-α-D-GLUCOPYRANOSYLADENOSINE HYDROCHLORIDE AND USE THEREOF
11/14/2013WO2013168455A1 Synergistic antidiabetic therapeutic agent
11/14/2013WO2013168437A1 Organic compound nanopowder, production method therefor, and suspension
11/14/2013WO2013168315A1 Therapeutic or prophylactic agent for dementia and behavioral and psychological symptoms
11/14/2013WO2013168131A1 Intrathecal administration of mtor inhibitors for the therapy of neurodegenerative, neuroinflammatory and neurooncologic diseases
11/14/2013WO2013168126A1 Crystalline forms of vilazodone hydrochloride and vilazodone free base
11/14/2013WO2013168096A1 Sterol derivatives and use thereof for treating diseases involving transformed astrocyte cells or for treating malignant haemopathies
11/14/2013WO2013168090A1 Geranium oil and constituents thereof for treatment of neurodegenerative diseases
11/14/2013WO2013168033A1 Compositions and methods for treatment of neurologic diseases
11/14/2013WO2013168032A1 Pharmaceutical compositions comprising rasagiline
11/14/2013WO2013168025A1 Compositions and methods for treatment of blood clotting disorders
11/14/2013WO2013168024A1 Prodrugs of anti-platelet agents
11/14/2013WO2013168023A1 Compositions and methods for treatment of parkinson's disease
11/14/2013WO2013168022A1 Compositions and methods for treating atherothrombosis
11/14/2013WO2013168021A1 Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
11/14/2013WO2013168019A1 Compositions and methods for the treatment of neuropathic pain
11/14/2013WO2013168016A1 Compositions and methods for the treatment of metabolic syndrome
11/14/2013WO2013168015A1 Compositions and methods for the treatment of asthma and allergy
11/14/2013WO2013168014A1 Compositions and methods for the treatment of familial amyloid polyneuropathy
11/14/2013WO2013168012A1 Compositions and methods for the treatment of respiratory disorders
11/14/2013WO2013168011A1 Compositions and methods for the treatment of chronic pain
11/14/2013WO2013168010A1 Compositions and methods for treatment of severe pain
11/14/2013WO2013168008A1 Compositions and methods for the treatment of neurological diseases
11/14/2013WO2013168007A1 Compositions and methods for the treatment of cardiovascular and neurological diseases
11/14/2013WO2013168003A1 Compositions and methods for the treatment of inflammation
11/14/2013WO2013168002A1 Compositions and methods for the treatment of neurological conditions
11/14/2013WO2013168001A1 Compositions and methods for the treatment of moderate to severe pain
11/14/2013WO2013168000A1 Compositions and methods for the treatment of severe pain
11/14/2013WO2013167996A1 Compositions and methods for the treatment of metabolic syndrome
11/14/2013WO2013167994A1 Compositions and methods for suppression of carbonic anhydrase activity
11/14/2013WO2013167993A1 Compositions and methods for the treatment of neurological degenerative disorders
11/14/2013WO2013167992A1 Compositions and methods for the treatment of inflammatory disorders
11/14/2013WO2013167991A1 Compositions and methods for the treatment of metabolic disorders
11/14/2013WO2013167990A1 Compositions and methods for the treatment of depression
11/14/2013WO2013167988A1 Compositions and methods for the treatment of cough
11/14/2013WO2013167987A1 Compositions and methods for the treatment of diabetes
11/14/2013WO2013167985A1 Compositions and methods for the treatment of neurological disorders
11/14/2013WO2013167963A1 Benzomorphan compounds as opioid receptors modulators
11/14/2013WO2013167959A1 Myrrh based composition for otological use
11/14/2013WO2013167909A1 Herpes simplex virus for the treatment of liver cancer
11/14/2013WO2013167906A1 Treatment of respiratory depression
11/14/2013WO2013167865A1 Pharmaceutical composition
11/14/2013WO2013167782A1 Amphiphilic copolymers carrying alpha-tocopherol having antitumoural properties
11/14/2013WO2013167770A1 Method for the synthesis of curcumin
11/14/2013WO2013167744A1 Rna products and uses thereof
11/14/2013WO2013167743A1 Use of compounds for the treatment of pain
11/14/2013WO2013167730A1 Alpha-carbolines for the treatment of cancer
11/14/2013WO2013167707A1 Composition for the treatment or prevention of urinary tract infections and dosage form
11/14/2013WO2013167698A1 Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer
11/14/2013WO2013167657A1 Parenteral esmolol formulation
11/14/2013WO2013167653A1 18f-labelled folate/antifolate analogues
11/14/2013WO2013167644A1 A composition comprising chlorophyllin as a green pigment
11/14/2013WO2013167640A1 Treatment of fish populations with lufenuron
11/14/2013WO2013167635A1 Therapeutic use of indole-dihydro-imidazole derivatives
11/14/2013WO2013167583A1 Pharmaceutical composition of a papillomavirus inhibitor
1 ... 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 ... 7860